Denali Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Denali Therapeutics Inc (DNLI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Denali Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 111M vs 133,968M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-35.8% annualized vs trailing 12 months), vs accelerating (+11.1%) for its tracked peer group.
- Profitability: Its 394.5% net margin compares with 23.6% for the peer group.
- Scale: Denali Therapeutics Inc ranks #27 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.4% of industry market cap.
- Peer revenue share: Denali Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.22M compares with $1.82M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DNLI Sales vs. its Competitors, Q3 2026
With a net margin of 394.45 %, Denali Therapeutics Inc achieved higher profitability than its competitors (23.61 %).
Denali Therapeutics Inc generated 0.05 % of the combined sales of its peer group.
API endpoints for this dataset
Denali Therapeutics Inc vs. its Competitors, Q3 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Denali Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Denali Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Denali Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Denali Therapeutics Inc's competitor groups requires a Commercial License.
Denali Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Denali Therapeutics Inc | - | - | - | Yes |
| Competitors combined (24) | ||||
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DNLI Stock Performance relative to its Competitors
DNLI Stock Performance relative to High-Confidence Competitors
DNLI Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alector Inc | 282.9% | Outperformed |
| 2 | Exelixis Inc | 282.9% | Outperformed |
| 3 | Halozyme Therapeutics Inc | 282.9% | Outperformed |
| 4 | Biogen Inc | 282.9% | Outperformed |
| 5 | Eli Lilly And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Denali Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Denali Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Denali Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Denali Therapeutics Inc |
3,855.00 | 110.69 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Gilead Sciences Inc |
208,779.39 | 30,988.00 |
 Biogen Inc |
36,706.13 | 10,297.30 |
 Exelixis Inc |
17,792.81 | 2,496.86 |
| SUBTOTAL | 1,760,769.75 | 175,710.61 |
Sign in to see all competitors of Denali Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Denali Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Denali Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Denali Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Eisai | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Biogen | Company report | 85% |
| Neumora Therapeutics Inc | Company report | 85% |
| Prevail Therapeutics | Company report | 85% |
| Genentech | Company report | 85% |
| Alector | Company report | 85% |
| Abbvie | Company report | 85% |
| Entrada Therapeutics Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Denali Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Denali Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Denali Therapeutics Inc .
Denali Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Denali Therapeutics Inc | 3,855 | 220,068 | 393,668 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 208,779 | 1,822,824 | -227,235 |
| Biogen Inc | 36,706 | 1,372,973 | 46,333 |
| Exelixis Inc | 17,793 | 2,176,862 | 1,454,397 |
| PEERS TOTAL | 1,756,915 | 1,821,292 | 344,225 |
Sign in to see all peers for Denali Therapeutics Inc .
Denali Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Gilead Sciences Inc | United States 76.66 % |
| Exelixis Inc | United States 92.47 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Denali Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Denali Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Denali Therapeutics Inc ranks #27 of 158 companies by market capitalization in its industry, holding 0.39 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 27 | Denali Therapeutics Inc | 3,759 | 0.39 % |
Market cap and industry share for the rest of Denali Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Denali Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 22 | Scholar Rock Holding Corp | 6,131 | 61.95 % |
| 23 | Crispr Therapeutics Ag | 4,832 | -13.96 % |
| 24 | Adaptive Biotechnologies Corporation | 4,473 | 57.82 % |
| 25 | Dbv Technologies S a | 4,437 | -31.21 % |
| 26 | Relay Therapeutics Inc | 1,234 | 12.3% |
| 27 | Denali Therapeutics Inc | 3,759 | 34.52 % |
| 28 | Iovance Biotherapeutics inc | 1,234 | 12.3% |
| 29 | Tarsus Pharmaceuticals Inc | 1,234 | 12.3% |
| 30 | Adma Biologics Inc | 1,234 | 12.3% |
| 31 | Vericel Corporation | 1,234 | 12.3% |
| 32 | Scinai Immunotherapeutics Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Denali Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Denali Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.3x | - |
| EV / EBITDA | - | 17.0x | - |
| P/B | 4.9x | 5.1x | -0.3x |
| Return on Equity | 21.40 % | industry aggregate | 27.47 % |
| Return on Invested Capital | -26.17 % | -11.80 % (avg) | -14.37 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Denali Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -79.34 % | 500.00 % | -85.50 % | 122.90 % | - | - | - |
| Operating Margin | -35.90 % | -799.10 % | 18.69 % | -607.78 % | -314.16 % | - | - | - |
| Return on Invested Capital | -4.30 % | -20.73 % | 3.68 % | -12.42 % | -18.07 % | -8.93 % | -17.79 % | -26.58 % |
| P/E | - | - | 442.8x | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Denali Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Denali Therapeutics Inc falls in the Dog quadrant: relative market share of 0.02x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Denali Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Denali Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Denali Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Denali Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Denali Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 27.5 points above the industry aggregate.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-35.8% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.02x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (58.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Denali Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Denali Therapeutics Inc | 2.28 | 8.30 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Biogen Inc | 0.08 | 2.33 | 0.38 |
| Exelixis Inc | 0.84 | 3.37 | - |
Sign in to see all peers for Denali Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Denali Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Denali Therapeutics Inc | Q3 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Biogen Inc | Q3 2026 | +10.6 % | - |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| PEERS TOTAL | +23.1 % | +6.7 % |
Sign in to see all peers for Denali Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Denali Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Denali Therapeutics Inc | Q3 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Biogen Inc | Q3 2026 | +11.0 % | -21.6 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
Sign in to see all peers for Denali Therapeutics Inc .
Denali Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Denali Therapeutics Inc | 16.42% | 17.88% | 21.40% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Biogen Inc | 1.13% | 1.26% | 1.86% |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
Sign in to see all peers for Denali Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Denali Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Denali Therapeutics Inc | - | 34.83 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Amgen Inc | 28.60 | 6.57 |
| Gilead Sciences Inc | - | 6.74 |
| Biogen Inc | 106.05 | 3.56 |
| Exelixis Inc | 28.63 | 7.13 |
| PEERS AVERAGE | 52.74 | 10.02 |
Sign in to see all peers for Denali Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.